OR-NUSCALE-POWER
9.12.2020 21:05:08 CET | Business Wire | Press release
NuScale Power today announced updated evaluations for the technical feasibility and economics of producing hydrogen using heat and electricity from a NuScale Power Module™ (NPM) as a result of the recent announcement that an NPM can generate an additional 25 percent more power per module for a total of 250 MWt (or 77 MWe) per module. The hydrogen study was originally conducted in 2014 with the Idaho National Laboratory and has been updated with new production and economic parameters.
The updated analysis found that with the 25 percent increase in power output of an NPM, one 250 MWt NuScale module is capable of producing 2,053 kg/hour of hydrogen, or nearly 50 metric tons per day, an increase from 1,667 kg/hour of hydrogen or 40 metric tons per day for a 200 MWt NuScale module. Moreover, as a result of the lower levelized cost of electricity from the increased power output, hydrogen produced by a NuScale high-temperature steam electrolysis (HTSE) system is forecasted to be cost competitive with high capacity factor renewable hydrogen cost estimates while also providing continuous, controlled hydrogen production.
“The ability of our NPM to now produce even more clean hydrogen, in a smaller footprint, is yet another example of how NuScale’s technology can help decarbonize various sectors of the economy while providing additional revenue streams for customers,” said Dr. José Reyes, Chief Technology Officer and Co-founder of NuScale Power. “Coupled with our proven design, unparalleled safety, and load following capabilities, this analysis further demonstrates that NuScale’s design is the gold standard in helping meet the demand for innovative solutions to challenging global energy needs.”
In the analysis, energy from a single NPM in the form of superheated steam and electricity are directly routed to a HTSE system operating at 850°C. Only 2 percent of the electrical output (~1.8 MWe) of the NPM is used to increase the process steam temperature from 300°C at the NPM outlet to 850°C for the electrolyzer. NuScale’s innovative multi-module power plant design means that a NuScale plant could produce reliable clean electricity for the grid while allocating one or more modules to economically produce hydrogen when electricity demand is low.
According to a recent report from LucidCatalyst , in order for the world to meet the Paris goals of keeping warming between 1.5–2°C, sufficient, low-cost, clean hydrogen production is needed to replace oil and gas in shipping, aviation, and industry. Over 95% of the world's hydrogen is currently produced using fossil fuels, with the most common method being steam methane reforming from natural gas. Renewables cannot produce all of this hydrogen alone, and advanced modular reactors will be required to produce enough clean hydrogen to displace the 100 million barrels of oil that are currently consumed around the world each day. Using a single NPM to produce 50 tons of hydrogen per day would avoid about 460 tons of CO2 emissions per day, or 168,000 tons of CO2 per year, as compared to producing hydrogen from natural gas. Additionally, NuScale’s ability to produce clean hydrogen is perfectly suited to assist in decarbonizing transportation, since a single NPM can produce enough hydrogen to power 38,000 fuel cell vehicles or 1,500 long-haul fuel cell trucks at average annual fuel usage rates in the United States.
About NuScale Power
NuScale Power has developed a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, and other process heat applications. This groundbreaking small modular reactor (SMR) design features a fully factory-fabricated NuScale Power Module™ capable of generating 77 MW of electricity using a safer, smaller, and scalable version of pressurized water reactor technology. NuScale's scalable design—a power plant can house up to four, six, or 12 individual power modules—offers the benefits of carbon-free energy and reduces the financial commitments associated with gigawatt-sized nuclear facilities. The majority investor in NuScale is Fluor Corporation, a global engineering, procurement, and construction company with a 60-year history in commercial nuclear power.
NuScale is headquartered in Portland, OR and has offices in Corvallis, OR; Rockville, MD; Charlotte, NC; Richland, WA; and London, UK. Follow us on Twitter: @NuScale_Power , Facebook: NuScale Power, LLC , LinkedIn: NuScale-Power , and Instagram: nuscale_power . Visit NuScale’s website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005943/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
